Activity of the neuroendocrine axes in patients with polymyalgia rheumatica before and after TNF-α blocking etanercept treatment

por Kreiner, Frederik Flindt, Galbo, Henrik
Publicado 2012

The potential of glucagon-like peptide-1 receptor agonists in heart failure

por Kreiner, Frederik Flindt, Hovingh, G. Kees Kornelis, von Scholten, Bernt Johan
Publicado 2022

Gene expression profiling in patients with polymyalgia rheumatica before and after symptom-abolishing glucocorticoid treatment

por Kreiner, Frederik Flindt, Borup, Rehannah, Nielsen, Finn Cilius, Schjerling, Peter, Galbo, Henrik
Publicado 2017

Surrogate endpoint evaluation using data from one large global randomized controlled trial

por Geybels, Milan, Wolthers, Benjamin Ole, Kreiner, Frederik Flindt, Rasmussen, Sren, Bauer, Robert
Publicado 2021

Glucagon‐like peptide‐1 receptor agonists to expand the healthy lifespan: Current and future potentials

por Kreiner, Frederik Flindt, von Scholten, Bernt Johan, Kurtzhals, Peter, Gough, Stephen Charles Langford
Publicado 2023

Insulin at 100: still central in protein-based therapy for chronic disease

por Kurtzhals, Peter, von Scholten, Bernt Johan, Kreiner, Frederik Flindt, Gough, Stephen Charles Langford
Publicado 2021

The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice

por von Scholten, Bernt Johan, Kreiner, Frederik Flindt, Rasmussen, Søren, Rossing, Peter, Idorn, Thomas
Publicado 2022

Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity

por Friedrichsen, Martin Haljeta, Endahl, Lars, Kreiner, Frederik Flindt, Goldwater, Ronald, Kankam, Martin, Toubro, Søren, Nygård, Sune Boris
Publicado 2023